Joshua Kantrowitz

Joshua Kantrowitz is a Professor of Clinical Psychiatry at Columbia University. His research focuses on biological psychiatry, specifically the neuropsychopharmacology and cognitive impairment associated with schizophrenia. His recent work includes a phase 2 randomized controlled trial of luvadaxistat for cognitive symptoms, meta-analyses of adjunctive trial effect sizes for negative symptoms, and studies on digital therapeutics and informant-based cognitive assessment. He also investigates psychopathology, neuropsychology, and translational approaches to improve clinical trial methodology and treatment outcomes in schizophrenia.